ANGSTROM AWARDED FIRST PATENT FOR CANCER TECHNOLOGY PLATFORM

Angstrom Pharmaceuticals, Inc., San Diego, Calif., has has been awarded an important first patent for its cancer technology platform.

This patent, U.S. Patent No. 5,942,492, "Cyclic Peptides That Bind To Urokinase-Type Plasminogen Activator Receptor" covers a broad class of cyclic peptides that Angstrom is developing to inactivate or alternatively to target a key receptor involved in the tumor angiogenesis and tumor metastasis. Urokinase-type plasminogen activator receptor (uPAR) that binds urokinase-type plasminogen activator (uPA) is found at the invasive edge of virtually all solid tumors including breast, prostate, colon, and lung,...